Last reviewed · How we verify

Acute Pancreatitis — Treatment Landscape & Competitive Intelligence

Acute Pancreatitis (disease) competitive landscape: 1 marketed treatments tracked, 0 Phase 3 candidates, 0 Phase 2 candidates. Recent regulatory actions and upcoming PDUFA dates across the entire treatment set.

1 marketed 0 Phase 3 0 Phase 2 Live · 30-min refresh

Marketed treatment landscape

Approved drugs treating Acute Pancreatitis, deduplicated by molecule. See the full disease page for line-of-therapy detail.

DrugGenericSponsorClassTargetLine of therapyFirst approval
early enteral nutrition early enteral nutrition Nanjing University School of Medicine Nutritional intervention / Dietary management strategy Gastrointestinal tract mucosa and intestinal barrier function

Phase 3 pipeline

No Phase 3 pipeline candidates tracked.

Phase 2 pipeline

No Phase 2 pipeline candidates tracked.

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this treatment set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this treatment set.

Sponsor landscape

  1. Nanjing University School of Medicine · 1 drug in Acute Pancreatitis

Subscribe to ongoing alerts

Every new regulatory action, PDUFA date, or trial completion in Acute Pancreatitis:

Cite this brief

Drug Landscape (2026). Acute Pancreatitis — Treatment Landscape & Competitive Intelligence Brief. https://druglandscape.com/ci/disease/acute-pancreatitis. Accessed 2026-06-10.

Related

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing